There is still time to register for Managing IP’s third annual US Patent Forum on March 25 at the Willard InterContinental, Washington D.C. ** Free for in-house patent counsel, academics and R&D professionals ** Supported by AIPLA and Delaware IP Law Blog, the forum will provide you with: • a guide to improving your company’sContinue reading “Managing IP US Patent Forum March 25, 2014 in Washington, D.C.”
Category Archives: General
Managing IP US Patent Forum – March 25, 2014
Managing IP invites you to the third annual US Patent Forum on March 25 at the Willard InterContinental, Washington D.C. ** Free for in-house patent counsel, academics and R&D professionals ** Supported by AIPLA and Delaware IP Law Blog, the forum will provide you with: • a guide to improving your company’s patent application processContinue reading “Managing IP US Patent Forum – March 25, 2014”
Jury returns defense verdict in Cellectis S.A. v. Precision Biosciences, Inc.
The jury returned a verdict Friday, May 3, 2013, in Cellectis S.A. v. Precision Biosciences, Inc., C.A. No. 11-173-SLR, finding that Precision Biosciences did not literally or indirectly infringe any claim of U.S. Patent No. 7,897,372, and that the asserted claims were invalid for obviousness and for lack of an adequate written description.
Managing IP’s U.S. Patent Forum, March 19, 2013 in Washington D.C.
Dear Colleague, Managing IP, in association with Delaware IP Law Blog, invites you to attend the second annual US Patent Forum March 19, 2013 at the Willard InterContinental in Washington D.C. http://www.managingip.com/USPatentForum2013 Free for in-house patent counsel, academics and R&D professionals. One year on from the AIA, we will assess the patent landscape in theContinue reading “Managing IP’s U.S. Patent Forum, March 19, 2013 in Washington D.C.”
Jury finds all asserted claims invalid, no infringement by any defendant.
After an eleven day trial before Chief Judge Gregory M. Sleet, a jury recently returned a defense verdict in litigation involving computer security products. Finjan, Inc. v. Symantec Corp., et al., C.A. No. 10-593 (GMS) (D. Del. Dec. 20, 2012). The jury found that none of the three defendants literally infringed the patents asserted againstContinue reading “Jury finds all asserted claims invalid, no infringement by any defendant.”
Jury finds that Apple’s iPhone infringes plaintiff’s valid patents.
A jury returned a verdict in favor of a plaintiff today, finding after a week long trial held before Judge Sue L. Robinson that Apple’s iPhone infringes three of the plaintiff’s patents: U.S. Patent Nos. 6,070,068; 6,253,075; and 6,427,078. MobileMedia Ideas, LLC v. Apple Inc., C.A. No. 10-258-SLR (D. Del. Dec. 14, 2012). The juryContinue reading “Jury finds that Apple’s iPhone infringes plaintiff’s valid patents.”
Trends in Delaware post-Twombly
Managing editor and co-author of Delaware IP Law Blog, Pilar G. Kraman, is a featured author in the latest issue of Managing IP’s, Intellectual Property Focus. This special “Americas IP Focus 2012” showcases commentary and analysis from IP lawyers throughout the Western Hemisphere, and is distributed to IP Owners and IP lawyers around the world.Continue reading “Trends in Delaware post-Twombly”
ABA Seeking Nominations for Annual Blawg 100
Hello readers, The ABA is taking nominations (through September 7, 2012) for their annual list of the 100 best legal blogs in various practice areas. You can nominate your favorite legal blogs at this link. Thanks for reading! Delaware IP Blog
Jury awards damages of $50 million based on 6% royalty rate for contributory and induced infringement of patent relating to enzyme replacement therapy to treat Fabry disease.
A jury recently awarded a plaintiff $50 million in damages based on a 6% royalty rate after finding that the defendant induced and contributed to the infringement of U.S. Patent No. 7,011,831 (“Recombinant α-galactosidase A therapy for Fabry disease”), and that the asserted claims were not invalid as anticipated, for failure to meet the writtenContinue reading “Jury awards damages of $50 million based on 6% royalty rate for contributory and induced infringement of patent relating to enzyme replacement therapy to treat Fabry disease.”
Jury verdict: all patents valid, infringement on both sides.
On April 27, 2012, the jury returned a verdict in Power Integrations, Inc. v. Fairchild Semiconductors International, Inc., et al., C.A. No. 08-309-LPS. The case involved infringement allegations by both the plaintiff and the defendants involving a total of six patents related to DC output power supplies or power converters. The jury found that FairchildContinue reading “Jury verdict: all patents valid, infringement on both sides.”
Delaware IP Law Blog 